Since the discovery in 1983 of HIV-1, the causal agent of AIDS [1], numerous antiretroviral drugs have been developed that target different steps of the retroviral cycle [2] . Today, HAART can improve dramatically the quality of life and life expectancy of infected individuals. Total eradication of HIV-1 has not been attained, however, because human reservoirs allow the provirus to survive despite an efficient immune response [3] . Moreover, under drug selection pressure, resistant viruses emerge rapidly owing to the poor fidelity of the viral DNA polymerase reverse transcriptase (RT) and the very high rate of HIV-1 multiplication [4] .
Since the discovery in 1983 of HIV-1, the causal agent of AIDS [1] , numerous antiretroviral drugs have been developed that target different steps of the retroviral cycle [2] . Today, HAART can improve dramatically the quality of life and life expectancy of infected individuals. Total eradication of HIV-1 has not been attained, however, because human reservoirs allow the provirus to survive despite an efficient immune response [3] . Moreover, under drug selection pressure, resistant viruses emerge rapidly owing to the poor fidelity of the viral DNA polymerase reverse transcriptase (RT) and the very high rate of HIV-1 multiplication [4] .
Until late 2007, only two viral enzymes (RT and protease) were targeted in clinical treatment by antiretroviral drugs in AIDS patients. The search for inhibitors directed against the viral integrase (IN), which is involved in the insertion of the proviral DNA genome into the host nuclear DNA, has exponentially increased over the past 10 years. This enzyme is difficult to target, because it is part of a multimeric nucleoprotein pre-integration complex involving viral and cellular components [5] . As a consequence, most of the inhibitors that were active on IN in vitro were not able to inhibit the enzyme when tested on HIV-1-infected cells. Nevertheless, an IN inhibitor, raltegravir (Merck Sharp & Dohme -Chibret, Paris, France) approved by the FDA in 2007, has been included in the HAART regimen of AIDS patients, showing that IN can be targeted in vivo [6] . The rational design of drugs targeting IN as undertaken for RT and protease is difficult, because of the lack of the full-length structure of this enzyme. However, the combinatorial SELEX strategy (Systematic Evolution of Ligands by EXponential enrichment) [7, 8] can be employed to find high-affinity aptamers able to inhibit this enzyme.
In the past decade, numerous synthetic oligonucleotides (ODN) have been proposed as promising anti-
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The guanine-quadruplex aptamer 93del inhibits HIV-1 replication ex vivo by interfering with viral entry, reverse transcription and integration Aurélie Faure-Perraud 1, 2, 3 , Mathieu Métifiot 1, 2, 4 , Sandrine Reigadas 2, 5 , Patricia Recordon-Pinson 2, 5 , Vincent Parissi 1, 2 , Michel Ventura 1, 2 , Marie-Line Andréola 1, 2 Introduction HIV drugs. A number of aptamers, some of them being guanine (G)-rich ODNs, that interact with HIV proteins such as RT [9] [10] [11] [12] [13] [14] , Tat protein [15, 16] and IN [17, 18] have been developed by the SELEX approach. In the case of IN, G-quartet ODNs (that is, DNA molecules containing runs of G that can form four-stranded structures) form a very stable structure that is responsible for IN inhibition in vitro. These ODNs potentially bind to the DDE catalytic site or surrounding charged residues, as reported for the ODN T30177 (17-mer; GTGGTGGGTGGGTGGGT) [19] .
In our laboratory, the SELEX strategy was used to identify a 16-mer ODN designated as 93del 5′-d(GGGGTGGGAGGAGGGT)-3′, which inhibits IN in vitro at nanomolar concentrations [20] . NMR studies showed that in the presence of K + ions the molecule adopts an unusually stable dimeric parallel-stranded DNA quadruplex [21] . Moreover, ODN 93del is able to block HIV-1 replication in infected cell cultures with a 50% inhibitory concentration of only 20 nM when added at the time of infection [22] . The very good selectivity index of this aptamer (>1,000) makes ODN 93del a very promising inhibitor with therapeutic potential.
However, because of their poor cellular uptake, it is generally accepted that most G-quadruplex-forming ODNs act primarily in vivo by inhibiting HIV entry into host cells. In particular, these ODNs are thought to bind to the viral gp120 protein, as in the case of the G-quadruplex T30177. The ex vivo inhibitory effect of T30177 was first attributed to its activity against both viral entry and integration [23] ; however, further studies using resistant viral strains carrying mutations in the gp120 gene confirmed a specific effect only on the viral entry process [24] .
Recently, we have shown that, unlike other G-quadruplex-forming ODNs, 93del can efficiently enter human cells. Moreover, its cellular uptake is greatly increased in the presence of the virus [25] . Given the ability of ODN 93del to cross the cell membrane, the main objective of this study was to test whether the observed effect of ODN 93del in vitro could be extrapolated to HIV-1-infected cells ex vivo. Here, we demonstrate that ODN 93del affects viral entry. Moreover, under conditions independent of viral access to the cell, ODN 93del also proved to be a very efficient inhibitor of intracellular early events of HIV-1 replication (that is, reverse transcription and integration).
Methods

Materials
Dextran sulfate sodium salt (DS) and 3′-azido-3′deoxy-thymidine (AZT) were obtained from Sigma-Aldrich (Saint-Quentin Fallavier, France). ODN 93del (GGGGT-GGGAGGAGGGT), ODN thrombin-binding aptamer (TBA) (GGTTGGTGTGGTTGG) and ODN 60delsc (GCGTGCGGGCGGCGAGAG) were obtained from MWG Biotech (Les Ulis, France).
Cell lines and viruses
HeLa P4 cells encoding a Tat-inducible β-galactosidase [26] were maintained in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Fisher Bioblock, Illkirch, France) supplemented with 10% inactivated fetal calf serum (FCS), 1 mg/ml geneticin (G418; Gibco-BRL, Fisher Bioblock, Illkirch, France). MT4 and H9 Laï cells were grown in RPMI 1640 Glutamax medium (Invitrogen) supplemented with 10% inactivated FCS.
HIV-1 viruses were obtained after 48 h coculture of MT4 cells (0.5×10 6 cells/ml) and H9 Laï cells (1×10 6 cells/ ml), chronically infected with HIV-1 Laï isolate, in RPMI 1640 Glutamax medium supplemented with 10% inactivated FCS at 37°C under humidified atmosphere and 5% CO 2 . The culture was centrifuged and the supernatant was clarified by filtration through a 0.45 µm membrane before freezing at -80°C.
Viral infectivity
Virus infectivity was assayed on HeLa P4 cells by assessing β-galactosidase activity. Briefly, cells were plated using 200 µl of DMEM medium (10% FCS) in 96-well plates at 10,000 cells per well. After overnight incubation at 37°C under humidified atmosphere and 5% CO 2 , the supernatant was discarded and 200 µl of viral preparation added in serial dilutions. After 24 h of infection, the supernatant was discarded and the wells were washed three times with 200 µl of phosphatebuffered saline (PBS). Each well was refilled with 200 µl of a reaction buffer containing 50 mM Tris-HCl pH 8.5, 100 mM β-mercaptoethanol, 0.05% Triton X-100 and 5 mM 4-methylumbelliferyl-B-d-galactoside (Sigma-Aldrich). After 24 h, the reaction was measured in a fluorescence microplate reader (Cytofluor II, Applied Biosystems, Courtaboeuf, France) at 360/460 nm excitation/emission.
Viral purification
HIV-1 Laï viruses (200 µl) were ultrafiltrated through a 0.02 µm Anopore membrane in 1.5 ml Vectaspin tubes (Whatman, Dutscher, Brumath, France) for 11 min at 5,000 g [27] . After three washes with PBS, the viral concentrate was resuspended in 250 µl of RPMI 1640 Glutamax medium (10% inactivated FCS). A 100 µl aliquot of each viral concentrate condition was used to infect 10,000 HeLa P4 cells per well.
Transfection assay
HeLa P4 cells were transfected with Lipofectamine 2000 (Invitrogen), according to manufacturer's instructions, with 1 µM (final concentration) ODN. Briefly, 24 h before transfection, cells were plated into 24-well plates at 100,000 cells/well and incubated at 37°C under humidified atmosphere and 5% CO 2. When cells were at 60-80% confluence, transfection complexes were mixed with 150 µl of DMEM medium and added to the cells. After 4 h, 150 µl of DMEM medium containing 20% FCS was added per well. Cells were further incubated for 20 h at 37°C under humidified atmosphere and 5% CO 2 before HIV-1 infection.
Drug-mediated inhibition kinetics
HeLa P4 cells were plated using 200 µl of DMEM medium supplemented with 10% FCS and 1 mg/ml G418 in a 96-well plate at 10,000 cells per well. After overnight incubation at 37°C, the supernatant was discarded and replaced by medium in the presence of HIV-1. Drug was added at different times after infection (from 0 to 10 h) and culture was maintained for 24 h. The β-galactosidase activity was measured in a fluorescence microplate reader.
Viral RNA extraction and quantitative RT-PCR
HeLa P4 cells were plated into 24-well plates at 100,000 cells per well and infected with HIV-1 virus. After 2 h, cells were washed three times with PBS. Trypsin treatment was performed to remove HIV-1 viruses attached to the cell membranes and to recover infected cells from the well. Cells were washed 3× with PBS. Total RNA was extracted using Trizol (Gibco-BRL), washed with 75% ethanol and dissolved in diethyl pyrocarbonatetreated water.
Primers for the glyceraldehyde phosphate dehydrogenase (GAPDH) cellular mRNA (sense primer 5′-G GAAGGTGAAGGTCGGAGTCAACGG-3′; antisense primer 5′-TCCTGGAAGATGGTGATGGGATTTC-3′) were used for amplification by SYBR Green realtime reverse transcriptase (RT) PCR. Quantitative RT-PCR was set up with the Iscript™ one-step RT-PCR kit (BioRad, Marnes-La-Coquette, France) in a 25 µl final volume with 300 nM of each primer, 0.5 µl RT and 10 µl RNA extract. The PCR program comprised 50°C for 10 min and 95°C for 5 min followed by 40 cycles (95°C 10 s, 62°C 30 s, 72°C 30 s) in a MyiQ real-time PCR thermocycler (BioRad).
To determine the amount of HIV-1 RNA, specific primers (sense primer LTRNec001 5′-GCCTCAATAAAGCTTGCCT-3′; antisense primer LTR131 5′-GGCGCCACTGCTAGAGAT-3′) were used with a real-time TaqMan MGB RT-PCR method (Applied Biosystems). The internal HIV-1 TaqMan probe (6-FAM-AAGTRGTGTGTGCCC-MGB; where R can be A or G) carried the 5′ reporter 6-carboxyfluorescein and the 3′ quencher 6-carboxytetramethylrhodamine (Applied Biosystems). Quantitative RT-PCR was set up in a 50 µl final volume with 25 µl buffer of SuperScript III Platinum One-step qRT-PCR (Applied Biosystems), 200 nM of each primer, 200 nM probe MGB, 1 µl ROX (passive reference dye), 1 µl RT and 10 µl RNA extract and analysed in an ABI Prism 7,000 Sequence Detection System thermocycler (Applied Biosystems). The PCR program comprised 48°C for 15 min followed by 55 cycles (95°C 2 min, 95°C 15 s, 60°C 30 s).
To determine cellular and viral RNA copy number, a standardization curve was performed with serial dilutions of in vitro transcribed GAPDH RNA (MEGAscript kit; Ambion, Applied Biosystems) and from solutions of HIV-1 RNA (AcroMetrix, Alkmaar, the Netherlands).
Viral DNA extraction and quantitative PCR
To quantify HIV-1 DNA, HeLa P4 cells were plated in 96-well plates at 10,000 cells per well and infected with HIV-1 Laï virus. After 24 h, cells were washed three times with PBS and trypsinized. Cells were washed 3× with PBS. Total DNA was extracted using the High Pure Viral Nucleic Acid kit (Roche Applied Science, Meylan, France) and subjected to quantitative PCR.
Quantification of viral DNA by gag PCR
Primers for the GAPDH cellular gene (sense primer 5′-G GAAGGTGAAGGTCGGAGTCAACGG-3′; antisense primer 5′-TCCTGGAAGATGGTGATGGGATTTC-3′) were used to verify by SYBR Green real-time PCR that equal DNA quantities were used in each PCR assay. Primers specific to a region of the gag gene (sense primer 5′-GCCTATTGCACCAGGCCAGAT-3′; antisense primer 5′-GTGAAGCTTGCTCGGCTCTTAGA-3′) were used to quantify total HIV-1 DNA present in infected cells. Quantitative PCR was set up in a 25 µl final volume with 12.5 µl buffer of PCR Quantitative SYBR Green kit (BioRad), 300 nM of each primer and 10 µl DNA extract. Cycling was programmed as 95°C for 1 min 30 s followed by 42 cycles (95°C 10 s, 60°C 20 s, 72°C 10 s) using a MyiQ real-time PCR thermocycler (BioRad). To determine gene copy number, a standardization curve was performed with serial dilutions of DNA from non-infected cells (GAPDH gene) and from pNL4-3 plasmid dilutions encoding viral genes (gag gene).
Amplification of integrated DNA
Phusion high-fidelity DNA polymerase (Ozyme, Saint Quentin en Yvelines, France) was used for the PCR amplification of integrated DNA. A 20 µl aliquot of DNA was added to a mix containing 500 nM primers, 200 nM dNTP and 10 µl 5× high fidelity buffer in a final volume of 50 µl. Primers were Alu-164 (5′-TCCC AGCTACTCGGGAGGCTGAGG-3′) and PBS-HIV-1 (5′-TTTCAGTCCCTGTTCGGGCGCCA-3′).
The PCR program comprised 30 s at 98°C followed by 35 cycles (10 s 98°C, 20 s 60°C, 2 min 30 s at 72°C) and 72°C for 5 min. A nested PCR was performed with the primers NI-1 (5′-CACACACAAGGCTACTTCCCT-3′) and NI-2 (5′-GCCACTCCCCAGTCCCGCCC-3′) using 5 µl of the products of Alu-PCR. The AmpliTaq Gold ® enzyme (Promega, Charbonnière, France) was used according to the program 12 min at 94°C, 42 cycles (94°C 1 min, 60°C 1 min, 72°C 1 min) and 7 min at 72°C.
2-Long terminal repeat DNA circles quantification
The 2-long terminal repeat (2-LTR) DNA circles were amplified with primers HIV-F and HIV-R1 spanning the LTR-LTR junction, as described elsewhere [28] . Two LTR junctions were amplified with 30 ng of total cellular DNA. The reaction mixture contained 12.5 µl of SYBR Green qPCR master mix 2× (Fermentas, St Remy les Chevreuses, France), 300 nM forward primer HIV-F (5′-GTGCCCGTCTGTTGTGTGACT-3′), 300 nM reverse primer HIV-R1 (5′-ACTGGTACTAGCTTGT AGCACCATCCA-3′) in a final volume of 25 µl; the amount of 2-LTR DNA circles was determined in a MyiQ real-time PCR thermocycler (BioRad). The PCR conditions were 95°C for 3 min followed by 42 cycles (95°C for 10 s, 60°C for 30 s, 72°C for 30 s) and 60°C for 10 s. Melting curves were performed by increasing set point temperature by 0.5°C (80 cycles of 10 s, starting from 60°C). The copy numbers of 2-LTR DNA circles were determined in reference to a standard curve prepared by amplification of quantities ranging from 10 to 10 6 copies of cloned DNA. The lowest detection limit of 2-LTR DNA using the SYBR Green qPCR was 10 copies of 2-LTR/assay.
Inhibition with vesicular stomatitis virus glycoprotein pseudotyped particles
Vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped particles were produced in HEK 293T cells by the platform of vectorology of IFR66 University of Bordeaux 2. Genomic RNA packaged in the viruses contained transgene coding for enhanced green fluorescent protein (EGFP) under the control of a cytomegalovirus promoter. Once in the target cells, viral RNA is reverse transcribed, imported into the nucleus and stably integrated into the host genome. Expression of EGFP was quantified by flow cytometry on a fluorescence-activated cell sorting Canto cytofluorimeter.
For quantification of integrated DNA by quantitative PCR, extraction of nucleic acids was performed with the High Pure Viral Nucleic Acid kit (Roche) and quantitative PCR was performed using the TaqMan ® PCR system. Lentiviral-F (5′-GGAGCTAGAACGATTCGCAGTTA-3′) and Lentiviral-R (5′-GGTTGTAGCTGTCCCAGTATTTG TC-3′) were used as primers and Lentiviral Probe (5′ -ACAGCCTTCTGATGTTTCTAACAGGCCAGG-3′; 5′-FAM-3′-MGB) as a probe.
Quantification of a housekeeping gene (RNase P; TaqMan RNase P Control Reagents Kit) was performed in parallel. A K562 cell line with 1 integrated copy/cell and a control line with 4 integrated copies/cell were used as reference.
Results
ODN 93del inhibits the early steps of HIV-1 infection
Inhibition of HIV replication HIV-1 inhibition by ODN 93del was previously assessed by incubating the compound with HeLa P4 cells at the time of infection and by monitoring β-galactosidase activity, expression of which (driven by the HIV-1 LTR) is linked to expression of the Tat protein [22] . In this study, ODN 93del was added at various concentrations at the time of infection and left within the culture medium throughout the experiment. Cells were infected for 24, 48 and 72 h prior to measuring viral replication, as described in the Methods section. Complete inhibition at all three time points tested was obtained with concentrations of 93del as low as 250 nM, suggesting a very potent inhibitory effect (Figure 1) .
In order to analyse the mechanism(s) involved in this inhibition, drug-mediated inhibition kinetics were performed ( Figure 2 ). Cells were infected at time 0 and several inhibitors were added to the cell culture at different time points from 0 to 10 h after infection. DS, which inhibits adsorption of the virus on the cell surface [29] , and AZT, which acts on reverse transcription [30] , were used as controls and compared with the effect of 500 nM ODN 93del. As shown in Figure 2A , total inhibition of HIV-1 replication was obtained when DS was added at the same time as the virus and also 2 h post-infection. The inhibitory effect of DS rapidly decreased and only 60% inhibition remained when the drug was added 4 h post-infection, confirming DS as an entry inhibitor. AZT was active when added at the same time as the virus and also 2 h post-infection. Moreover, inhibition by AZT reached 80% when added 4 h postinfection and 50% inhibition still remained even 6 h post-infection, as expected for an inhibitor of reverse transcription. As for the other molecules, ODN 93del was active when added at the time of infection and remained efficient in the first hours post-infection: 50% inhibition was observed when added 4 h post-infection. These results suggest that ODN 93del affects the very early steps of the HIV-1 replication cycle during the first hours of infection. However, there is no real statistical difference between the kinetics of DS and AZT, showing that this assay is not sensitive enough to discriminate between inhibitors of entry and reverse transcription.
Inhibition of vesicular stomatitis virus glycoprotein pseudotyped particles
The inhibition profile shown in Figure 2A indicates that ODN 93del inhibits the very early steps of viral replication. To estimate the percentage of HIV-1 inhibition due to entry, experiments were performed with viruses bearing VSV-G envelopes. In this experiment, entry is independent from the interaction between gp120 and CD4. Cells were infected with viruses bearing the VSV-G envelope in the presence of increasing concentrations of ODN 93del ( Figure 2B ). Fluorescence of cells owing to EGFP expression (see Methods) was measured by flow cytometry 2 days and 7 days after infection. Inhibition of infection of VSV-G pseudotyped viruses was observed, as described for HeLa P4 cells infected with viruses bearing the gp120 envelope (Figure 1 ), but was much weaker. These results clearly showed that ODN 93del might act at the entry level (in a gp120-independent way) or at a post-entry level. To clarify this point, ODN 93del was added 6 h post-infection. The same level of inhibition was observed when ODN 93del was added at the time of infection or 6 h post-infection, suggesting that inhibition of VSV-G pseudotyped particles occurred at a post-entry level. Experiments were performed to quantify integrated DNA. Cells were infected with VSV-G pseudotyped viruses in the presence of increasing concentrations of ODN 93del added at the time of infection. Inhibition of infection was confirmed by measuring the fluorescence of cells by flow cytometry (Table 1) . Extraction of nucleic acids was performed and quantitative PCR was used to quantify the integrated DNA. As shown in Table 1 , the number of copies of integrated DNA decreases when the ODN 93del concentration increases and perfectly matches the percentage of fluorescent cells.
The decrease in integrated DNA could be due to the inhibition of integration or to inhibition of several steps occurring before integration. The following experiments were performed to clarify the mechanism of inhibition.
ODN 93del acts on the infectivity of HIV-1 isolated particles
As G-quadruplex-forming ODNs have been shown to inhibit HIV entry by interacting with the gp120 envelope protein, we investigated the effect of ODN 93del on the isolated HIV-1 particle. Briefly, viruses were incubated at room temperature in the presence of different concentrations of the inhibitor and then treated intensively with three washes with PBS through Vectaspin columns to eliminate unbound ODN 93del. The infectivity of viral particles pre-incubated with the aptamer was studied using the HeLa P4 system, as described above.
To determine the effect of incubation at room temperature on HIV-1 infectivity, viral particles were incubated for different times and used to infect HeLa P4 cells (untreated viruses). In parallel, viruses were submitted to three washes with PBS through a Vectaspin column and suspended in culture media prior to HeLa P4 cell infection (centrifuged viruses). As shown in Figure 3A , the infectivity of the untreated viruses was not affected by 60 min incubation at room temperature, although 120 min incubation showed a slight decrease in replication (20%). However, centrifugation after 60 min of incubation at room temperature induced a more dramatic effect on viral infectivity, with more than 20% loss of viral replication. As incubation for 30 min at room temperature did not show any significant differences between untreated and centrifuged virus, this condition was chosen for further investigations.
As controls, the effects of two other molecules were first studied. The TBA, a 15-mer ODN able to form G-quartets [31] , has no effect on HIV-1 replication [22] . At a concentration of 1 µM, ODN TBA showed only a weak inhibition of HIV-1 infectivity ( Figure  3B ). Described in our laboratory, VD-84 is a Curiepyridinone compound that acts as a non-nucleoside inhibitor of RT and has antiviral activities in the nanomolar range in human infected cells [20, 27, 32] . VD-84 completely inhibited the infectivity of pretreated viral particles ( Figure 3B ) as already shown, probably due to its high affinity for RT [27] . Incubation of HIV-1 particles with serial dilutions of ODN 93del showed a clear dose-dependent inhibition ( Figure 3B ). Near complete inhibition was obtained with 10 µM ODN 93del (50% inhibitory concentration 1 µM). Therefore, ODN 93del, which interacts with the viral particle [25] , is able to inhibit HIV-1 infectivity. 
ODN 93del affects reverse transcription
The inhibition of HIV-1 replication ex vivo when ODN 93del was added simultaneously with the virus led to a greater inhibition of infectivity ( Figure 1 ) than preincubation of ODN 93del with the isolated particle ( Figure 3B ). This observation suggests that other intracellular steps of the viral cycle could be affected. To investigate more precisely the effect of ODN 93del on the early steps of infection, quantification of viral RNA and DNA was performed. Cells were infected in the presence of increasing concentrations of inhibitor. After 2 h infection, cells were treated with trypsin, washed and total RNA was extracted to be quantified by real-time RT-PCR. Figure  4A shows a 50% decrease in HIV-1 RNA with only 10 nM of ODN 93del; the level of HIV-1 RNA was not affected by increasing the inhibitor concentration. This result shows that ODN 93del acts on the rate of HIV-1 RNA synthesis in infected cells and that cellular entry of viral particles, as measured by the total amounts of viral RNA in infected cells, was reduced. An RT-PCR control performed without reverse transcriptase shows a 10% amplification of contaminant DNA (-RT lane) present in the RNA sample.
We next quantified the reverse transcribed DNA in the presence of ODN 93del. Cells were infected in the presence of various inhibitor concentrations and the culture was maintained for 24 h. Cells were washed and total DNA was then extracted, as described in the Methods section. Amplification of the gag gene was used to measure HIV-1 total DNA by quantitative PCR. As shown in Figure 4B , a dose-dependent inhibition was observed with increasing ODN 93del concentration. The HIV-1 DNA quantity detected in infected cells with 200 nM of ODN 93del was about 5% of the control. Under these conditions, a 50% decrease in the viral RNA level was observed as compared to when the inhibitor was absent, indicating that ODN 93del had an effect either on reverse transcription or on the stability of viral DNA.
ODN 93del affects HIV-1 proviral integration in infected cells
The previous results showed inhibition of viral entry when ODN 93del was added to cell cultures at the time of infection; however, ODN 93del is a very potent inhibitor of HIV-1 IN in vitro [14] . To study the intracellular effect of ODN 93del, it was important to overcome the effect of the inhibitory aptamer on viral entry. For this purpose, transfection experiments were performed, thereby ruling out any eventual interactions between the virus and the aptamer outside of the cell. Several agents were assayed, but not all were suitable to perform viral infection after transfection (not shown). Lipofectamine 2000 TM , which is non-cytotoxic under our conditions, was chosen for further investigations.
Different quantities of a preformed ODN 93del-Lipofectamine 2000 complex were incubated with cells for 24 h. Before infection by HIV-1, cells were washed three times with PBS to eliminate the free inhibitory aptamer or ODN 93del-Lipofectamine 2000 complexes that did not enter the cells. After 24 h, viral replication was determined as described above ( Figure  5A ). No inhibition was observed when a control ODN 60delsc (a non-inhibitory 16-mer G-rich ODN) complexed with Lipofectamine 2000 was tested [22] (Figure 5A) . Serial dilutions of ODN 93del-Lipofectamine 2000 complexes induced inhibition with a maximum of 80% inhibition for an equivalent of 1 µM of inhibitor.
A significant inhibition of HIV-1 replication by transfection complexes was observed. This inhibition was weaker than compared with the effect of ODN 93del alone, as demonstrated previously [22] (Figure 1 ), probably because of the involvement of an intracellular target or owing to the presence of Lipofectamine 2000. To verify this point, integrated DNA was specifically amplified using Alu-PCR followed by a nested PCR. Viral integration was affected by the presence of ODN 93del-Lipofectamine 2000 complexes in a dose-dependent manner ( Figure 5B; lanes 15, 16, 17) . To see if inhibition is occurring at the integration level, quantification of 2-LTR circles and total DNA was performed by quantitative PCR. Cells were infected after transfection with 1 µM ODN 93del-Lipofectamine 2000 complex. 2-LTR DNA circles and total viral DNA were quantified 24, 48, 72 and 96 h post-infection and compared with DNA quantification in the absence of ODN 93del. As shown in Table 2 , the ratio of 2-LTR DNA copies:total DNA copies shows little variation when infection is performed in the absence of inhibitor. In the presence of the ODN 93del-Lipofectamine 2000 complex, the ratio of 2-LTR DNA copies:total DNA copies indicates an increase in 2-LTR DNA circles with a peak 3 days post-infection and a decrease thereafter. This observation suggests that ODN 93del inhibits IN reaction in vivo (Table 2 and Figure 6 ). These results are in full agreement with the profile of evolution of 2-LTR circles that we observed in a previous work in the presence of raltegravir [33] , an established IN inhibitor used in therapy. Moreover, the number of total DNA copies is less in the presence of transfected ODN 93del-Lipofectamine 2000 complex than in the absence of inhibitor, suggesting an effect on the reverse transcription step (Table 2) . Altogether, these results show that ODN 93del inhibits viral entry, but also acts at a post-entry level. telomeric regions at the end of chromosomes [34] . Numerous G-quadruplex-forming ODNs have been identified as promising anticancerous [35, 36] and anti-HIV drugs [19] . The integration step in the HIV-1 life cycle is a very attractive target, because of its essential role in viral replication. Several G-quadruplex ODNs have been identified as IN inhibitors in vitro [19] .
We previously identified ODN 93del, an aptamer showing a potent in vitro inhibitory effect on IN and on ex vivo HIV-1 infectivity [20, 22] . In the present study, the ex vivo viral target of ODN 93del was studied. ODN 93del is able to act on the very early steps of the HIV-1 cycle. Greatest inhibition was obtained when the inhibitor and the virus were added simultaneously, complete inhibition being reached with as little as 250 nM ODN 93del ( Figure 1 ). Moreover, pre-incubation of viral particles with ODN 93del prior to infection decreased the viral infectivity, indicating an interaction between ODN 93del and the viral particle, as previously suggested [25] . Although obtained with higher concentrations of aptamer than when ODN 93del and viruses were added together to HeLa P4 cells, this inhibitory effect of HIV-1 replication suggests a very interesting potential of 93del as a microbicide, an advantage that has never previously been demonstrated for a G-quartet ODN. This microbicidal effect might be due to an interaction between the viral particle and ODN 93del; however, one hypothesis would be that part of the ODN can enter the virus, which could explain why the inhibition of entry is not dose-dependent. Another possibility is that saturation of gp120 binding is attained at the concentration used, because viral concentrations used in infection experiments are quite high compared with conditions of infection in vivo, or that some viruses can enter the cells by another route other than through the gp120-CD4 interaction (endocytosis, for example). In addition to affecting viral entry, ODN 93del inhibits the early intracellular steps of HIV-1 replication. Although the level of RNA is constant between 10 and 200 nM of ODN 93del, the level of DNA decreases in a dose-dependent manner (Figure 4 ), strongly suggesting a decrease in RT activity. This might be due to the fact that ODN 93del derives from another longer aptamer that was initially selected against the RNase H domain of RT [20] , which is responsible for an enzymatic activity crucial for HIV-1 replication. Even if ODN 93del does not inhibit RNase H activity in vitro, a different situation might occur in cells.
In a previous work we showed that ODN 93del is able to enter cells and that its uptake is increased by the presence of HIV-1 [25] . The virus might act as a vector. If so, there would be interaction between a viral surface component and the aptamer, thus facilitating entry of ODN 93del into the target cell. Alternatively, ODN 93del might benefit from the interaction of HIV-1 with the target cell during the entry process. This in turn would explain why the aptamer inhibits viral entry and why it facilitates the internalization of the ODN into the cell, leading to the inhibition of reverse transcription and integration. In fact, the inhibition of IN has been linked to an effect on reverse transcription during the viral cycle [37, 38] , because the two retroviral enzymes, RT and IN, are present in the pre-integration complex and are able to interact in vitro [39] . Thus, the intracellular inhibition of IN might lead to a decrease in reverse transcribed DNA. Because other hypotheses are also plausible, additional experiments are needed to determine whether increased DNA degradation is due to the lower level of viral DNA, to the partial degradation of the RNA template or to improper tRNA primer annealing under these conditions. We needed to demonstrate that intracellular inhibition by the aptamer was independent of the effect on viral entry. Firstly, an inhibitory activity was observed by using transfection ( Figure 5A ). Secondly, we found that when ODN 93del was added 24 h before infection without washing, it was not degraded and had the same inhibitory effect as when added at the time of infection (not shown). Moreover, when ODN 93del was added 24 h before infection and then washed before adding the virus, no inhibition was observed (AF-P et al., data not shown). Thirdly, when PCR experiments were performed with the DNA from cells infected in the presence of ODN 93del-Lipofectamine 2000 complexes, a clear inhibition was observed. The concentration of ODN 93del necessary to obtain a similar level of inhibition was higher in the presence of the aptamer complexed to Lipofectamine 2000 than when used alone ( Figure 5 ). This might be due to the fact that the intracellular concentration of active complexed inhibitor is hard to quantify and cannot be compared with the original concentration of ODN complexed to the transfection reagent. Moreover, the release of ODN from ODN 93del-Lipofectamine 2000 complexes once inside the cell is likely to be necessary for the inhibitor to reach its target, and might be a limiting step. Nevertheless, the effects of ODN 93del on viral entry, which could be partially responsible for the inhibition with uncomplexed ODN, were ruled out in the transfection assays, thus clearly showing that the integration step is affected by ODN 93del independently of viral entry.
Our previous work showed that ODN 93del is a potent in vitro inhibitor of HIV-1 IN [22] . The ex vivo mechanism of inhibition of this molecule has been elucidated: ODN 93del has an original mechanism of inhibition by interfering with different steps in the viral cycle. ODN 93del inhibits viral entry, as do other G-quartet ODNs; however, it can exert an inhibitory effect on two other steps of viral infection, reverse transcription and integration. Moreover, its high affinity for viral particles as well as its increased cellular internalization in the presence of HIV-1 particles suggests its use as a potential microbicide. Some of these microbicides, in particular polyanions (PRO2000), are in clinical development [40] . In the absence of a vaccine, prevention of HIV transmission during sexual intercourse and treatment with HAART in infected individuals are the best ways of slowing down the AIDS epidemic. ODN 93del might become a leader in the search for new microbicidal drugs, an area of research that is now highly promising.
